Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

solaria2

  • Home
  •  
  • solaria2



  • Most Read
  • Latest Comments
  • Patient recruitment finalised for scar treatment trials being led by Professor Fiona Wood
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Patient recruitment finalised for scar treatment trials being led by Professor Fiona Wood
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Patient recruitment finalised for scar treatment trials being led by Professor Fiona Wood
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Patient recruitment finalised for scar treatment trials being led by Professor Fiona Wood
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Patient recruitment finalised for scar treatment trials being led by Professor Fiona Wood
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars
    Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars
    • News

  • Pharmaxis accelerates clinical drug developments with additional resources via sale of mannitol business to Arna Pharma
    Pharmaxis accelerates clinical drug developments with additional resources via sale of mannitol business to Arna Pharma
    • News

  • Garvan Institute preclinical study identifies potential of Pharmaxis drug to boost pancreatic cancer survival rate by 35%
    Garvan Institute preclinical study identifies potential of Pharmaxis drug to boost pancreatic cancer survival rate by 35%
    • News

  • Encouraged by interim data, FDA approves Pharmaxis to expand its myelofibrosis treatment trials
    Encouraged by interim data, FDA approves Pharmaxis to expand its myelofibrosis treatment trials
    • News

  • Pharmaxis delivers impressive Phase 2 clinical data to treat myelofibrosis, pushing on to FDA discussions
    Pharmaxis delivers impressive Phase 2 clinical data to treat myelofibrosis, pushing on to FDA discussions
    • News

  • Patient recruitment finalised for scar treatment trials being led by Professor Fiona Wood
    • News

    Patient recruitment finalised for scar treatment trials being led by Professor Fiona Wood

    While clinical trials could be tricky for companies who struggle to convince fearful and pessimistic volunteers to participate, luckily this is not the case for clinical stage drug developer Pharmaxis (ASX: PXS). The Company has wrapped up patient recruitment of its topical anti scarring drug PXS-6302, with the last of the 42 patients dosed earlierRead More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.